Table 1.
Patients’ clinical characteristics.
| Parameters | n = 30 |
|---|---|
| Age (years) | 70 (53–77) |
| Female, n (%) | 24 (80.0) |
| BSA (m2) | 1.54 (1.45–1.68) |
| With PH, n (%) | 23 (76.7) |
| mPAP ≥30 mmHg, n (%) | 12 (40.0) |
| WHO functional class (I/II/III/IV) | 2/18/8/2 |
| Oxygen inhalation, n (%) | 13 (43.3) |
| 6MWT | |
| Walking distance (m) | 410 (349–460) |
| Lowest SpO2 (%) | 89 (86–91) |
| Prescriptions (PH-targeted therapy) | |
| Single therapy, n (%) | 4 (13.3) |
| Dual therapy, n (%) | 2 (6.7) |
| Riociguat, n (%) | 5 (16.7) |
| ERA, n (%) | 1 (3.3) |
| PGA, n (%) | 2 (6.7) |
| Past history of BPA, n (%) | 3 (10.0) |
| Laboratory data | |
| eGFR (mL/min per 1.73 m2) | 57.8 (46.9–76.0) |
| BNP (pg/mL) | 26.0 (12.4–82.2) |
| Pulmonary function test | |
| %VC (%) | 105.4 (89.2–117.3) |
| %FEV1.0 (%) | 102.0 (82.9–106.5) |
| FEV1/FVC | 72.5 (69.4–76.0) |
| DLCO (%) | 86.3 (72.1–105.9) |
| DLCO/VA | 3.75 (3.50–4.15) |
Data are presented as median (interquartile range). BSA, body surface area; PH, pulmonary hypertension; mPAP, mean pulmonary arterial pressure; 6MWT, 6 min walking test; SpO2, oxygen saturation; ERA, endothelin receptor antagonist; PGA, prostaglandin analog; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; %VC, percent vital capacity; FEV1.0%, percent forced expiratory volume in 1 s; DLCO, diffusing capacity of the lung for carbon monoxide; DLCO/VA, diffusing capacity of the lung for carbon monoxide/alveolar ventilation.